These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 35522395)

  • 1. Management of Pharmacologic Adverse Effects in Advanced Liver Disease.
    García-Cortés M; García-García A
    Clin Drug Investig; 2022 Jun; 42(Suppl 1):33-38. PubMed ID: 35522395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analgesics in patients with hepatic impairment: pharmacology and clinical implications.
    Bosilkovska M; Walder B; Besson M; Daali Y; Desmeules J
    Drugs; 2012 Aug; 72(12):1645-69. PubMed ID: 22867045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatotoxicity in patients with liver disease.
    Andreasen PB
    Arch Toxicol Suppl; 1978; (1):131-6. PubMed ID: 277091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver.
    Piñeiro-Carrero VM; Piñeiro EO
    Pediatrics; 2004 Apr; 113(4 Suppl):1097-106. PubMed ID: 15060205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acetaminophen-induced hepatic necrosis. II. Role of covalent binding in vivo.
    Jollow DJ; Mitchell JR; Potter WZ; Davis DC; Gillette JR; Brodie BB
    J Pharmacol Exp Ther; 1973 Oct; 187(1):195-202. PubMed ID: 4746327
    [No Abstract]   [Full Text] [Related]  

  • 6. Drug administration in chronic liver disease.
    Westphal JF; Brogard JM
    Drug Saf; 1997 Jul; 17(1):47-73. PubMed ID: 9258630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The therapeutic use of acetaminophen in patients with liver disease.
    Benson GD; Koff RS; Tolman KG
    Am J Ther; 2005; 12(2):133-41. PubMed ID: 15767831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatotoxicity following the therapeutic use of antipyretic analgesics.
    Benson GD
    Am J Med; 1983 Nov; 75(5A):85-93. PubMed ID: 6359871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-medications that modulate liver injury and repair influence clinical outcome of acetaminophen-associated liver injury.
    Suzuki A; Yuen N; Walsh J; Papay J; Hunt CM; Diehl AM
    Clin Gastroenterol Hepatol; 2009 Aug; 7(8):882-8. PubMed ID: 19362607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drugs and the liver: advances in metabolism, toxicity, and therapeutics.
    Buratti S; Lavine JE
    Curr Opin Pediatr; 2002 Oct; 14(5):601-7. PubMed ID: 12352255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-induced hepatic disorders. Incidence, management and avoidance.
    Døssing M; Sonne J
    Drug Saf; 1993 Dec; 9(6):441-9. PubMed ID: 8129864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet-activating factor (PAF) involvement in acetaminophen-induced liver toxicity and regeneration.
    Grypioti AD; Theocharis SE; Papadimas GK; Demopoulos CA; Papadopoulou-Daifoti Z; Basayiannis AC; Mykoniatis MG
    Arch Toxicol; 2005 Aug; 79(8):466-74. PubMed ID: 15995853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Acetaminophen and the liver: damage at therapeutic dose levels?].
    Petersen KU
    MMW Fortschr Med; 2011 Dec; 153 Suppl 4():137-42. PubMed ID: 23964475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blockade of the receptor for advanced glycation end products attenuates acetaminophen-induced hepatotoxicity in mice.
    Ekong U; Zeng S; Dun H; Feirt N; Guo J; Ippagunta N; Guarrera JV; Lu Y; Weinberg A; Qu W; Ramasamy R; Schmidt AM; Emond JC
    J Gastroenterol Hepatol; 2006 Apr; 21(4):682-8. PubMed ID: 16677153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastrointestinal safety and tolerability of oral non-aspirin over-the-counter analgesics.
    Moore N; Scheiman JM
    Postgrad Med; 2018 Mar; 130(2):188-199. PubMed ID: 29417856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic effects of acetaminophen. Enhanced toxicity in alcoholics.
    Maddrey WC
    J Clin Gastroenterol; 1987 Apr; 9(2):180-5. PubMed ID: 3553308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Dangerous drugs in hepatic insufficiency].
    Isal JP; Caulin C
    Med Chir Dig; 1979; 8(5):447-9. PubMed ID: 534025
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction.
    Verbeeck RK
    Eur J Clin Pharmacol; 2008 Dec; 64(12):1147-61. PubMed ID: 18762933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glutamine preserves liver glutathione after lethal hepatic injury.
    Hong RW; Rounds JD; Helton WS; Robinson MK; Wilmore DW
    Ann Surg; 1992 Feb; 215(2):114-9. PubMed ID: 1546897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic drug interactions in liver disease: An update.
    Palatini P; De Martin S
    World J Gastroenterol; 2016 Jan; 22(3):1260-78. PubMed ID: 26811663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.